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We summarize the existing literature data concerning the involvement of skeletal muscle (SM) in whole body glucose homeostasis
and the contribution of SM insulin resistance (IR) to the metabolic derangements observed in several endocrine disorders,
including polycystic ovary syndrome (PCOS), adrenal disorders and thyroid function abnormalities. IR in PCOS is associated
with a unique postbinding defect in insulin receptor signaling in general and in SM in particular, due to a complex interaction
between genetic and environmental factors. Adrenal hormone excess is also associated with disrupted insulin action in peripheral
tissues,suchasSM.Furthermore,bothhyper-andhypothyroidismarethoughttobeinsulinresistantstates,duetoinsulinreceptor
and postreceptor defects. Further studies are deﬁnitely needed in order to unravel the underlying pathogenetic mechanisms.
In summary, the principal mechanisms involved in muscle IR in the endocrine diseases reviewed herein include abnormal
phosphorylation of insulin signaling proteins, altered muscle ﬁber composition, reduced transcapillary insulin delivery, decreased
glycogen synthesis, and impaired mitochondrial oxidative metabolism.
1.Introduction
Insulin resistance (IR) constitutes a common and broadly
prevalent metabolic disorder, which seems to govern the
pathophysiology of diabetes mellitus, metabolic syndrome,
and obesity [1]. Furthermore, IR appears to be a clinically
important manifestation of various endocrine diseases,
including polycystic ovary syndrome (PCOS), thyroid and
adrenal diseases, as well as their complications [2–5]. From
a pathophysiological point of view, IR appears to be the end
result of a complex interaction between genetic predisposi-
tion and environmental factors.
In general, IR indicates the presence of an impaired
peripheral tissue response to endogenously secreted insulin.
It is typically manifested as both decreased insulin-mediated
glucose uptake (IMGU) at the level of adipose and skeletal
muscle (SM) tissue, and as an impaired suppression of
hepatic glucose output. A signiﬁcant body of evidence
supports the critical role of SM for the development of
IR, most commonly through an interactive cross-talk with
adipose and liver tissue [6–8].
2.SkeletalMuscleandGlucose Homeostasis
SM plays a crucial role in maintaining systemic glucose
metabolism, accounting for 85% of whole body insulin-
stimulated glucose uptake [7]. In SM, insulin stimulates
glucose uptake by increasing the translocation of glucose
transport molecules, mainly GLUT4, from intracellular
vesicles to the cell surface [9]. This process is initiated
upon binding of insulin to the transmembrane receptor
and is mediated through an intracellular molecular signal-
ing cascade, including the consecutive phosphorylation of
several cytosolic proteins, such as insulin receptor substrate
molecules (IRS), phosphatidylinositol 3-kinase (PI3K), and
protein kinase B (PKB/Akt) [9]. To date, among the four
diﬀerent IRS molecules that have been cloned, IRS-1 and
IRS-2 appear to be the predominant isoforms expressed in
SM.IRSmoleculesserveasdockingsitesforspeciﬁcsignaling
p r o t e i n s ,s u c ha sP I 3 K ,a n dp l a yak e yr o l ef o rd o w n s t r e a m
insulin signaling [9]. Recent studies have proposed four dif-
ferent PI3K isoforms in human SM, involved in the insulin-
dependent PI3K signaling pathways [9]. These isoforms2 Journal of Biomedicine and Biotechnology
elicit diﬀerent, rather speciﬁc, insulin-induced responses.
Although the exact molecular link between PI3K and glucose
transport has not been fully elucidated yet, protein kinase B
(PKB) or Akt (Akt/PKB) and members of the protein kinase
C (PKC) family have been suggested as important molecules
in the metabolic pathway of insulin-signaling, leading ulti-
mately to increased intracellular glucose transport [9].
The activated insulin-signaling cascade results in the
release of GLUT4 from an intracellular reservoir compart-
ment and its translocation and ﬁnal fusion with the plasma
membrane. This is the rate-limiting step for the uptake of
glucose, which is transported across the plasma membrane
and further processed by either oxidative (glycolysis) or
nonoxidative pathways (glycogen synthesis) [9].
However, glucose disposal in SM is not entirely indepen-
dentfromthemetaboliceﬀectsofinsulinonotherperipheral
tissues, such as adipose tissue (AT). It seems that IR at the
level of SM might be also secondarily induced to adipose
tissue IR. More speciﬁcally, it has been shown that mice with
AT-speciﬁc knockout of GLUT4 had an impaired IMGU in
SMaswell,despitepreservedGLUT4expressioninthistissue
[6]. Moreover, AT overexpression of GLUT4 reversed the
impaired IMGU observed in SM-speciﬁc GLUT4 knockout
mice, without concomitantly restoring glucose transport
in SM [8]. These experimental ﬁndings have highlighted
the importance of interactive communication (cross-talk)
between AT and SM in terms of regulating glucometabolic
balance.
3.Skeletal MuscleandInsulinResistance
SM is a principal tissue responsible for IMGU which has
recently gained a lot of interest, as a major site involved
in peripheral IR. Most of the available data have derived
from studies in type 2 diabetes mellitus (T2DM), where
SM has emerged as an important insulin-resistant peripheral
tissue, via molecular mechanisms that are currently being
extensively investigated.
In vitro and in vivo data from humans and laboratory
animals support a selective insulin-signaling defect at the
level of glucose transport in SM. In type 2 diabetic patients,
IMGU in SM has been found to be signiﬁcantly reduced by
about 50%, without clarifying whether this is a permanent
defect or rather a short-term downregulation secondary
to the diabetic state. Furthermore, an additional possible
explanation for the development of IR in SM is related to
speciﬁc alterations in the insulin-signal transduction path-
way, including decreased IRS-1 protein content, impaired
IRS-1 phosphorylation, reduced PI3K activity, or altered
protein expression of the regulatory subunit of PI3K [9, 10].
Alterations in the expression or translocation of GLUT4 to
the plasma membrane have been also implicated as potential
pathogenetic mechanisms. However, whether these defects
are actually a primary cause of IR or rather a secondary
eﬀect to an altered metabolic milieu remains still unresolved
[11].
Despitetheconsiderablebodyofevidencesupportingthe
critical role of SM for the development of IR in many clinical
entities, the exact underlying mechanisms have not been
fully delineated and most commonly represent a complex
interaction between multiple extrinsic and intrinsic factors.
3.1. The Role of Adipokines in Skeletal Muscle IR. Most
commonly, IR in SM is considered to be the end result
of a complex interaction involving several diﬀerent tissues.
AT can induce IR at the level of SM via secretion of
adipokines, inﬂammatory mediators, and growth factors.
Tumor necrosis factor α (TNF-α), adiponectin, and leptin
are the main adipokines that appear to be implicated in the
development of cross-communication between AT and SM.
TNF-α is the main autocrine/paracrine AT-derived fac-
tor, triggering the release of free fatty acids (FFAs) from
AT into bloodstream circulation. This is mainly dependent
on nuclear factor κB( N F κB) activation and is mediated
by the suppression of many genes responsible for glucose
and FFA uptake and utilization [12, 13]. TNF-α-mediated
FFA release impairs insulin-signaling in insulin responsive
peripheral tissues such as SM [10]. According to the lipid
supply hypothesis, the increased FFA availability provides
the predominant substrate for intermediate metabolism,
resulting in increased NADH/NAD+ and acetyl-CoA/CoA
ratios. Elevated FFA concentrations promote beta-oxidation,
which diminishes glucose uptake and oxidation. In parallel,
FFA clearance is decreased and their storage as triglyceride
droplets in SM is signiﬁcantly enhanced [14].
In addition, adiponectin, a protective adipokine secreted
by adipocytes, plays a pivotal role for SM insulin sensitivity.
Adiponectin stimulates FFA catabolism, either directly or
indirectly through stimulation of PPAR-γ nuclear receptors,
and promotes a marked decrease of circulating FFA and glu-
coselevels [15].Lastbut not least,leptin, a hormone secreted
predominantly by AT, acts both on hypothalamus and on
target tissues including SM and is signiﬁcantly involved in
the regulatory mechanisms determining peripheral insulin
action and sensitivity [16].
3.2. Defects in Skeletal Muscle Glycogen Synthesis. The pri-
mary site of postabsorptive glucose disposal is SM and
the primary mechanism of glucose storage is through its
conversion to glycogen. In states of IR, a deﬁciency in the
nonoxidative glucose disposal has been primarily related
to a defect in glycogen synthesis. Freymond et al. studied
biopsies of vastus lateralis muscle, both before and during a
hyperinsulinemic-euglycemic clamp, and demonstrated that
human subjects with IR display decreased insulin-stimulated
glycogen synthase activity [17]. This defect at the level of
glycogen synthase activity and thus glycogen synthesis in
SM, provides a further pathogenetic mechanism, underlying
systemic and muscle IR.
3.3. Glucocorticoids and Muscle IR. Chronic glucocorticoid
excess, a typical biochemical feature of Cushing’s syndrome,
hasbeentraditionallyassociatedwithIRingeneral.However,
recent experimental observations suggest that glucocor-
ticoids, as well as glucocorticoid receptor (GR) activity,
can have adverse eﬀects on peripheral insulin sensitivity.
Reynolds et al., found increased GR mRNA levels and
increased expression of glucocorticoid receptors in SM ofJournal of Biomedicine and Biotechnology 3
menwithIRandhypertension,implicatingthedysregulation
of glucocorticoid receptor expression and/or function as a
possible underlying pathogenetic mechanism for IR in SM
[18].
3.4. Skeletal Muscle Vascular Bed, Blood Flow, and Insulin
Action. Insulin-mediated increased blood ﬂow seems to
be an important step for insulin delivery and glucose
metabolism in peripheral tissues, including SM [19]. This
theory was ﬁrst introduced by Baron, et al. who showed
a remarkable correlation between insulin-mediated whole
body glucose uptake and leg blood ﬂow over a broad
spectrum of insulin sensitivities in normal and IR states
[20].Thesecorrelationsweretypicallyobservedseveralhours
after the initiation of an insulin clamp, namely, under steady
state conditions [21, 22]. In addition, metacholine infusion
increased leg blood ﬂow and glucose uptake, while these
were diminished after L-N-monomethyl arginine infusion
[23]. The above observations support the important role of
insulin-mediated blood ﬂow for glucose uptake and insulin
action.
Insulinregulatesbloodﬂowinperipheraltissuesthrough
a variety of mechanisms. Insulin induces dilatation of termi-
nal arterioles and provides a constant rate of vasodilatation
or vasoconstriction, in order to maximally extend the period
of peripheral tissue perfusion. In this way, insulin enhances
nutrient delivery and expands the surface area available
for exchange of insulin, glucose, and other nutrients in
peripheral tissues, including SM. Furthermore, after its
binding to the receptor, insulin seems to promote its own
translocation across the endothelial cell barrier [24]. Most
of the research work in this ﬁeld has been conducted on
skin microvasculature [25], without, however, ensuring that
the insulin-mediated vascular responses observed in skin
reﬂect also those in SM. Although far more data need to be
obtained, it is currently proposed that various factors impair
the insulin-mediated vascular response and tissue delivery of
nutrients such as glucose and insulin, mediating the process
of IR in SM.
4. MuscleInsulinResistance and
EndocrineDisease
Although generalized and muscle IR remains a hot topic
for the investigation of metabolic disease, it would be quite
interesting to expand this research to a number of common
and clinically relevant endocrine diseases, including PCOS,
adrenal dysfunction, and thyroid disorders.
4.1. PCOS and Muscle IR. PCOS is a common endocrine
disorder with a worldwide prevalence of 6%-7% among
premenopausal women [26]. However, despite its steadily
increasing prevalence, the fundamental underlying defect
remains still speculative and seems to be multifactorial
in origin. Beyond the reproductive abnormalities (chronic
anovulatory dysfunction, infertility), women with PCOS
display several metabolic abnormalities as well, including
disorders of glucose metabolism and insulin action, which
underlie the increased risk of developing impaired glucose
tolerance and type 2 diabetes [27].
Women with PCOS exhibit basal hyperinsulinemia,
decreased glucose-stimulated insulin release and IMGU, due
to reduced hepatic insulin clearance and pancreatic β-cell
dysfunction. In addition, they exhibit a generalized IR,
which mainly involves an impaired insulin responsiveness of
adipose tissue and SM [2, 28].
IR in PCOS is associated with a unique postbinding
defect in insulin receptor signaling due to a complex interac-
tion between intrinsic (genetically determined) and environ-
mental factors [29]. It is supported that the disrupted insulin
receptor tyrosine kinase activity in adipocytes and IRS-1-
associated PI3K activity in SM are the key elements in the
IR pathogenetic process [30]. In addition, extrinsic factors
including inﬂammatory mediators, adipokines, androgens,
free fatty acids (FFAs), amino acids, and increased glucose
levels have been all implicated in the pathogenesis of IR in
PCOS.
4.1.1. Adipokines, Inﬂammatory Mediators, FFAs, and Muscle
IR in PCOS. In vitro studies have shown that cultured
SM cells from women with PCOS display normal insulin
sensitivity, while SM cells from in vivo studies in PCOS
exhibit resistance to insulin, suggesting the important role
of extrinsic factors in producing muscle IR in PCOS
[28]. Among them, adipokines, TNF-α, FFAs, amino acids,
androgens, and increased glucose levels have been all
postulated to be involved in the pathogenesis of IR in
PCOS [31]. Increased TNF-α levels and elevated plasma
interleukin-6 (IL-6) concentrations have been consistently
reported in both obese and normal weight women with
PCOS, indicating the signiﬁcant contribution of chronic
low-grade inﬂammation to IR [32, 33]. As far as leptin is
concerned, Pehlivanov and Mitkov reported higher serum
leptin in PCOS demonstrating a positive correlation with IR,
independently of markers of adiposity [34]. Data regarding
adiponectin and resistin levels are rather conﬂicting in
womenwithPCOS.Theseadipokineshavebeenfoundeither
increased or conversely decreased, depending on the obesity
status of the studied population [35, 36].
The existing data indicate that adipose tissue, which
is also an insulin resistant site in PCOS, and especially
when it is centrally accumulated, secretes increased levels
of adipokines, FFA, and inﬂammatory mediators (TNF-α,
IL-6), which in turn promote IR at the level of SM via a
vicious cycle. In particular, elevated FFA levels have been
consistently suggested in PCOS, especially when increased
visceral fat is also present. This was well described by Ek et
al. who reported an increased rate of visceral fat lipolysis in
PCOS, suggesting a genetically determined upregulation in
visceral fat lipolysis, associated with a selective increase in
the function of both protein kinase A (PKA) and hormone-
sensitive lipase (HSL) [37]. It is obvious that the increased
FFA inﬂux has detrimental eﬀects for insulin metabolic
signaling in SM [28, 37].
4.1.2. Androgens and Muscle IR. Multiple studies suggest the
association between androgen excess and IR in women with4 Journal of Biomedicine and Biotechnology
PCOS, but their cross-sectional nature does not allow safe
conclusions about causality [31].
On one hand, hyperandrogenemia in women with PCOS
appears to be an eﬀect of the augmented steroidogen-
esis by hyperinsulinemia secondary to IR [38, 39]. On
the other hand, hyperandrogenemia induces generalized
and muscle IR, through either a direct eﬀect of andro-
gens on insulin action in AT and SM, or indirectly by
aﬀecting lipid metabolism and body fat distribution [31].
Hyperandrogenemia-inducedIRisselective,aﬀectingmainly
the metabolic but not the mitogenic actions of insulin,
since insulin-stimulated ovarian steroidogenesis is perfectly
maintained [40]. Androgen excess has been associated with
some of the typical insulin-signaling defects in PCOS [41].
Most of these eﬀects have been mostly studied in female
rats, while there is a relative paucity of similar clinical
studies. Testosterone administration to female adult rats for
8–12 weeks caused hyperinsulinemia in both intact and
ovariectomized animals [42], while in the latter it induced
a 50% reduction in IMGU into SM. Impaired SM insulin
action was combined with fewer type 1 muscle ﬁbers (slow
twitch, oxidative) and increased type 2 ﬁbers (fast twitch,
insulinresistant).Inthesamestudy,adecreasedSMcapillary
density and an impaired muscle glycogen synthase activity
were also reported, contributing to the observed IR of SM
[43]. It seems that postinsulin receptor signaling events
are involved in testosterone-induced IR in SM in this rat
model. In support of this, experimental data in primary
diﬀerentiated rat myotubes have demonstrated a synergistic
interaction between testosterone and insulin in phosphory-
lation of intracellular signaling proteins (phosphorylation of
IRS-1atserineresidues),resultinginadissociationofinsulin
receptor from the PI3K signaling cascade and an impaired
insulin metabolic signaling [44].
Summarizing the existing data, androgens promote IR
at the tissue level of SM by reducing capillary network
formation for adequate delivery of insulin to SM, switching
muscle ﬁber isoforms, reducing glycogen synthase activity
and impairing insulin-mediated GLUT4 plasma membrane
translocation [44].
However, the ﬁnding of hyperinsulinemia in PCOS
patients raises the questions what the cause is and what the
eﬀect is. Most of the existing clinical data suggest, without
providing deﬁnitive conﬁrmation, that hyperinsulinemia
causes hyperandrogenism, more than the other way around
[45].
4.1.3. Molecular Defects and Muscle IR in PCOS
(a) In Vitro and In Vivo Studies. Current evidence suggests
that excessive serine phosphorylation of the insulin receptor
or downstream signaling molecules plays a pivotal role for
the pathogenesis of muscle IR in PCOS [46]. In vitro studies
in cultured SM cells from obese and nonobese patients
with PCOS reported an abnormal phosphorylation pattern,
consisting in decreased tyrosine autophosphorylation of
the insulin receptor and increased serine phosphorylation,
similarly to the phosphorylation abnormalities observed in
PCOS cultured skin ﬁbroblasts [46].
Corbould et al. who studied cultured SM cells of
obese nondiabetic women with PCOS and of age- and
BMI-matched control women, did not observe a decrease
in IMGU and basal autophosphorylation in vitro, while
insulin-stimulated tyrosine phosphorylation of the insulin
receptor was found to be normal [29]. Moreover, the
protein expression of insulin receptor β-subunit, IRS-2,
PI3K, and GLUT4 was similar to that of controls. How-
ever, a number of molecular signaling abnormalities were
documented including a 35% increased expression and a
two-fold increased constitutive phosphorylation of IRS-1 at
serine 312, decreased IRS-1-associated PI3K activity after
adjusting for the increased expression of IRS-1, decreased
baseline IRS-2-associated PI3K activity, a tendency for
decreased insulin-stimulated IRS-2-associated PI3K activity,
and higher GLUT1 expression, being positively correlated
with increased basal glucose uptake in PCOS SM [29]. The
apparently normal insulin response of PCOS SM in terms of
glucose uptake is possibly attributed to the increased IRS-1
and GLUT1 expression. Furthermore, the fact that IMGU
is maintained in vitro but signiﬁcantly impaired in vivo
indicates that IR is not an intrinsic feature in PCOS SM
but is greatly inﬂuenced by adverse in vivo environmental
conditions.
A putative serine kinase, extrinsic to the insulin receptor,
has been implicated in the abnormal pattern of phospho-
rylation in PCOS but has not been identiﬁed yet. Although
there are at least 50 known potential serine/threonine
phosphorylation sites on IRS-1, phosphorylation at both
serine 312 and serine 636/639 has been frequently reported
in several studies associating IRS-1 serine phosphorylation
with IR [47].
The defective activation of aPKC (atypical protein kinase
C), a downstream eﬀector of PI3K, in SM of PCOS obese
patients has been also involved in the pathogenesis of muscle
IR in this syndrome. In humans, marked defects in aPKC
activation in SM have been reported in T2DM, obesity,
obesity-associated PCOS, and impaired glucose tolerance
[48]. These defects in aPKC activation in SM are due to
both impaired activation of IRS-1-dependent PI3K and
diminished responsiveness of aPKCs to a lipid product of
PI3K, called PI-3,4,5-(PO4)3 or PIP3. Although it is still
uncertain which underlying defect comes ﬁrst, the resultant
defect in aPKC activation in SM contributes signiﬁcantly to
the development of muscle IR [48].
Despite the well established identiﬁcation of several
molecular abnormalities in PCOS, it remained initially
unclear whether the observed defects in insulin-signaling are
actually intrinsic, genetically determined to SM, or rather
acquired secondary to exposure to in vivo environmen-
tal factors such as hyperinsulinemia, hyperandrogenemia,
increased circulating FFAs, or sustained hyperglycemia.
According to Corbould et al. muscle IR is not an intrinsic
feature in PCOS but appears rather to be signiﬁcantly
inﬂuenced by endogenous environmental factors [29].
Indeed, exposure to a number of molecules, including
FFA,TNF-α,glucose,aminoacids,diacylglycerol(DAG),and
fatty acyl-CoA, increases serine phosphorylation of IRS-1
and results in impaired insulin-signaling. These moleculesJournal of Biomedicine and Biotechnology 5
are thought to act on IRS-1 through a variety of ser-
ine/threonine kinases including mTOR (mammalian target
of rapamycin) and S6K. More speciﬁcally, FFA reduce IRS-
1-associated PI3K activity, impair Akt/PKB phosphoryla-
tion, and activate PKCθ (protein kinase C theta), a serine
kinase that increases serine phosphorylation of IRS-1 [28].
Concerning diacylglycerol, a potent activator of PKC, it is
thought to be an additional important lipid mediator of
muscle IR [49]. High insulin levels can also stimulate IRS-
1 serine phosphorylation in human myoblasts, indicating
that insulin can modulate its own signaling pathway [44].
Androgen excess induces muscle IR in PCOS by aﬀecting,
most possibly, postinsulin receptor signaling events. Recent
in vitro data, in primary diﬀerentiated rat myotubes, have
demonstrated a synergistic interaction between testosterone
and insulin in phosphorylation of intracellular signaling
proteins (phosphorylation of IRS-1 at serine residues) and
a consequent dissociation of the insulin receptor from
the PI3K signaling cascade, resulting in impaired insulin
metabolic signaling [44].
(b) Human Studies. In vivo studies of PCOS patients, where
serial SM biopsies were performed during hyperinsulinemic-
euglycemicclamps,haverevealedasigniﬁcantimpairmentin
IMGU, an increased expression of IRS-2, and normal expres-
sion of insulin receptor, IRS-1, and PI3K. These data suggest
that the increased expression of IRS-2 might represent a
compensatoryadaptationforthedecreasedinsulin-mediated
IRS-1-associated PI3K activity, which is not, however, com-
pletely eﬀective, since IMGU was not restored to normal
[50]. Most recently, Hojlund et al. reported small reductions
in insulin-stimulated phosphorylation of Akt (PKB) and
AS160 (Akt substrate of 160kDa) in intact muscle of women
with PCOS, which was partially reversed by treatment with
insulin-sensitizing agents such as pioglitazone [51].
Recently, another candidate pathogenetic mechanism for
muscle IR in women with PCOS has been proposed, consist-
ing in a defective insulin regulation of ERK 1/2 (extracellular
signal-regulated kinases 1/2). Rajkhowa et al. compared
the relative contribution of two distinct insulin-signaling
pathways to muscle IR in nine women, diagnosed with
PCOS. The study involved the Ras-ERK and the IRS-PKB
pathways, mediating the mitogenic and metabolic eﬀects of
insulin, respectively, and found no signiﬁcant diﬀerence in
the expression, basal activity, or insulin activation of IRS-1
andPKBbetweenPCOSsubjectsandcontrols[52].However,
there was a severe attenuation of insulin stimulation of
the ERK pathway and an accompanying trend for higher
basal phosphorylation of ERK 1/2 in SM biopsies obtained
from nearly all women with PCOS [52]. Interestingly, the
investigators observed a reduced ERK activity after acute in
vivo exposure of SM to insulin, in almost all PCOS subjects
of the study, contrasting with the physiologically expected
increase in mitogenic ERK activity, in response to insulin
stimulation. These results suggest that ERK activation might
inﬂuence regulation of glucose uptake in SM and might be
involved in muscle IR in women with PCOS [52].
Based on the few existing human in vivo studies, it
seems that in PCOS there is a severe functional defect in
the insulin-signaling cascade within SM, consisting in an
abnormal phosphorylation pattern of the insulin receptor or
downstream key signaling proteins.
4.1.4. Transcriptional Defects Involved in Muscle IR in PCOS.
It has been recently demonstrated that PCOS is associated
with impaired mitochondrial structural integrity and oxida-
tive metabolism. Skov et al. studying insulin resistant women
with PCOS, demonstrated a signiﬁcant downregulation
of the expression of nuclear-encoded genes representing
mitochondrial oxidative phosphorylation, ribosomal pro-
teins, mRNA processing reactome, translation factors, and
proteasome degradation (OXPHOS), compared to control
women. This eﬀect was mainly mediated by a decrease
in PGC-1a expression (PPAR-γ coactivator-1a) and was
partially restored after treatment with pioglitazone [53].
Thus, the insulin-sensitizing eﬀects of pioglitazone may
include reversal of preexisting abnormalities in ribosomal
proteinbiosynthesisandmitochondrialbiogenesisinwomen
with PCOS [54].
Calcium transporter activity was also signiﬁcantly down-
regulated in PCOS patients. Increasing evidence sup-
ports a modulating role for calcium inﬂux, calmodulin
and Ca+2/calmodulin-dependent protein kinase (CaMK) in
IMGU in SM [55]. An increase in cytosolic calcium and
activation of CaMK induce mitochondrial biogenesis and
GLUT4 expression via activation of diﬀerent transcription
factors, including NRF-1 and -2 (nuclear respiratory factor)
and the coactivator PGC-1a [56]. Any potential dysreg-
ulation of calcium homeostasis could, therefore, have a
pronounced disturbing eﬀect on IMGU and mitochondrial
functional capacity [57].
Future studies, unraveling the exact molecular mecha-
nisms of IR in general or in SM in particular in PCOS,
may help develop eﬀective gene-based strategies in order to
prevent the increased risk of early onset type 2 diabetes in
women suﬀering from this condition.
4.2. Adrenal Disorders and Muscle IR. Adrenal disorders
characterized by increased secretion of adrenocortical or
adrenomedullary hormones such as hyperaldosteronism,
Cushing’s syndrome, hyperandrogenism, and pheochro-
mocytoma have been associated with various metabolic
disorders, including impaired glucose tolerance, IR, and
overt diabetes [58]. These abnormalities constitute the end
result of the adverse eﬀects of adrenal hormones on various
components of insulin action and glucose metabolism.
Adrenal hormone excess is associated with decreased
insulin secretion by the pancreatic β cell or disrupted insulin
action in peripheral tissues. SM has been recently recognized
as an important insulin-target site with a major role in the
pathogenesis of the glucometabolic abnormalities associated
with hypersecreting adrenal disorders [59].
4.2.1. Aldosterone Excess and Muscle IR. Aldosterone is
the ﬁnal mediator of the renin-angiotensin-aldosterone
system (RAS), which mediates blood pressure control and
electrolytic balance in the kidney. However, a signiﬁcant
body of evidence indicates that aldosterone—in concert6 Journal of Biomedicine and Biotechnology
with other independently acting mediators of RAS axis
(renin and angiotensin)—impairs insulin secretion and
metabolic signaling, resulting in impaired glucose tolerance
and overt diabetes. Focusing on aldosterone, which can be
signiﬁcantly elevated in some patients with hypersecreting
adrenal lesions, it promotes IR, inﬂammation, ﬁbrosis,
oxidative stress, and sodium retention, with detrimental
cardiometabolic eﬀects [60]. Recent literature data sup-
port that most of the adverse metabolic changes observed
in primary hyperaldosteronism can be totally reversed
after the surgical removal of the adrenal tumors or
treatment with mineralocorticoid receptor blocking agents
[61].
Mounting evidence supports that aldosterone exerts its
diabetogenic actions by a direct eﬀect on insulin recep-
tor function and metabolic signaling cascade in several
peripheral tissues, including cardiovascular and renal tissue,
fat, liver and SM [60]. In addition, hypokalemia, as a
result of aldosterone excess, can also impair both pancreatic
insulin secretion and peripheral insulin action, providing
an alternative explanation for the observed abnormalities in
primary hyperaldosteronism [62].
However, the underlying molecular and cellular mech-
anisms linking aldosterone excess with changes in the glu-
cose and insulin metabolism remain still elusive, especially
regarding the contribution of SM.
Inadditiontoitsclassiceﬀects,aldosteroneinducesrapid
(nongenomic) adverse responses in both vascular smooth
muscle cells and SM. This eﬀect is mediated by NADPH
oxidase (nicotinamide adenine dinucleotide phosphate),
which generates excess reactive oxygen species (ROS), redox
imbalance, and oxidative stress [63]. Oxidative stress acti-
vates redox-sensitive serine kinases in these tissues, includ-
ing PKC (protein kinase C), MAPKs (mitogen-activated
protein kinases), c-Jun NH2-terminal kinase, extracellular
signal-regulated kinases 1 and 2 (ERK 1/2), and p-kinase.
The activation of these kinases leads to increased serine
phosphorylation of IRS-1, which impairs normal binding
with PI3K and results in decreased activation of PKB (Akt)
and adverse downstream metabolic eﬀects such as impaired
glucose transport in many tissues, including SM [64]. This
eﬀectisfurthersubstantiatedbythesigniﬁcantimprovement
in systemic insulin sensitivity, insulin-signalling, and glucose
uptake by SM, after treatment with mineralocorticoid recep-
tor blocking agents in experimental animal models of RAS
hyperactivation and IR [65]. The improvement in insulin
sensitivitywascloselyassociatedwithdecreasedNADPHoxi-
dase activity in SM, suppressed levels of ROS, and improved
mitochondrial structure and function. In addition, in rat
vascular smooth muscle cells, aldosterone downregulated
IRS-1 expression via stimulating the production of ROS, an
eﬀect which was markedly attenuated by treatment with the
selective mineralocorticoid receptor antagonist eplerenone
[66].
4.2.2. Glucocorticoid Excess and Muscle IR. Chronic exposure
to glucocorticoid excess, a typical feature of Cushing’s
syndrome, is associated with various metabolic disorders,
including glucose intolerance, IR, or overt diabetes [67].
Glucocorticoids (GCs) interfere with several steps of glu-
cose metabolism and insulin-signaling cascade, resulting in
reduced IMGU and IR in most peripheral tissues, including
SM. GCs may induce IR, either directly by interfering with
the insulin receptor cascade in SM, or indirectly through
GC-induced changes in protein and lipid metabolism
[67].
Since studies into the eﬀects of GCs on the expression
of insulin receptor in SM have yielded contradictory results,
the markedly reduced IMGU under conditions of GC excess
has been proposed as a postreceptor defect. In vitro studies
using isolated SM cells treated with dexamethasone showed
a decreased expression and phosphorylation of IRS-1, PI3K,
and PKB/Akt as well as reduced GLUT4 migration to
the cell surface [68, 69]. In addition to reducing glucose
uptake, GCs have also been shown to decrease glycogen
synthesis rate in Wistar rats by reducing PKB/Akt and
GSK-3 (glycogen synthase kinase-3) phosphorylation [70].
Beyond experimental results, there are limited available data
concerning the exact molecular eﬀects of GCs on insulin-
signaling in humans. As early as in 1988, Rebuﬀ´ e-Scrive, was
the ﬁrst investigator who studied in detail the morphology
and metabolism of SM in female patients with Cushing’s
syndrome [71]. In his study, leg muscle tissue of women
with Cushing’s syndrome was found to contain a relatively
low proportion of type I ﬁbers (insulin sensitive) and a high
proportion of type IIb ﬁbers (insulin resistant), a similar
pattern of muscle ﬁber composition to that observed in
android obesity. He also found a signiﬁcantly low glycogen
synthase activity in the lateral vastus muscle of the same
women.Thisistheﬁrststudysuggestinganabnormalmuscle
ﬁbercomposition(relativeshiftfromtypeItotypeIIbﬁbers)
in a common clinical condition of chronic endogenous
corticosteroid excess. In addition, healthy volunteers treated
with dexamethasone for 5 days and patients exposed to long-
term high-dose GCs after renal transplantation, displayed
reducedglycogensynthesis rateswithconcomitantdecreased
concentration and activity of glycogen synthase in SM
biopsies [72].
Some data support an indirect eﬀect of GS on SM
insulin-signaling, which is mediated through enhanced
proteolysis, and thus increased circulating amino acid levels.
Elevated circulating amino acids seem to inhibit insulin-
stimulated IRS tyrosine phosphorylation and activation of
PI3K in vitro [73]. In addition, they reduce IMGU and
glycogen synthesis in humans [74].
Another indirect negative eﬀect of GCs on SM insulin
sensitivity appears to be mediated through the GC-induced
dyslipidemia. GCs promote whole body lipolysis, resulting
in increased plasma levels of FFAs, which enhance in turn
the accumulation of intramyocellular lipids (IMCLs), such
as fatty acyl CoA, diacylglycerol, and ceramide, aﬀecting
negatively glucose uptake and disposal [75]. It was originally
proposed by Randle in 1963 that intracellular lipids decrease
insulin-mediated glucose uptake by competing with glucose
for oxidation [76]. However, more recent studies have
demonstrated that IMCLs reduce IMGU by interfering
directly with insulin-signaling. Intracellular lipids may acti-
vate various serine kinases, such as c-Jun aminoterminalJournal of Biomedicine and Biotechnology 7
kinase (JNK) and IKB kinase-β (IKK-β), which phospho-
rylate serine sites on IRS-1, resulting in suppressed insulin-
signaling [75].
In summary, GCs reduce insulin sensitivity and con-
sequently IMGU in SM, not only by directly perturbing
insulin-signalingandglycogensynthesis,butalsosecondarily
to unfavorable changes in protein and lipid metabolism,
which further aﬀect negatively the insulin-signaling cascade,
in peripheral tissues, including SM.
4.2.3. Adrenal Androgens and Muscle IR. The exact relation-
ship between increased adrenal androgens and IR remains
to be elucidated. It has been shown that experimentally
induced hyperinsulinemia elicited an acute decline in dehy-
droepiandrosterone (DHEA) and dehydroepiandrosterone
sulfate (DHEA-S). However, the regulatory role of insulin
on adrenal androgen production and metabolism in normal
physiology ordisease remainsstill speculative[58].Inseveral
animal models, DHEA appears to exert potent antiobesity
and antidiabetogenic actions, but such eﬀects have not been
persuasively demonstrated in humans [58]. Human studies
on DHEA are limited, and more research needs to be
conducted in order to determine whether the experimental
observationsmadeinanimalmodelscanbealsoextrapolated
to man. Recent experimental evidence indicates that DHEA
may act at multiple steps in the regulation of glucose
metabolism in the liver, suppressing the activity of hepatic
gluconeogenic enzymes [77]. However, there are no data
concerning the relationship of increased adrenal androgen
production and peripheral insulin action, especially at the
level of SM.
4.2.4. Catecholamine Excess and Muscle IR. Pheochromocy-
toma, typically characterized by endogenous catecholamine
excess, is associated with several glucometabolic abnor-
malities, ranging from impaired glucose tolerance (25%–
75%) to overt diabetes [78]. The main underlying patho-
genetic mechanism for pheochromocytoma-associated glu-
cose dysmetabolism is the catecholamine-induced decreased
insulin secretion through a2 adrenoreceptors, while the
eﬀects of catecholamines on peripheral glucose uptake seem
to be less important [79]. However, in animal studies,
epinephrine has been shown to induce IR in rat muscle
[80]. Furthermore, Raz et al. [81] studied the eﬀect of
epinephrine in eight healthy patients and detected an inhi-
bition of insulin-mediated glycogenesis because of an inac-
tivation of glycogen synthase, suggesting that epinephrine
inhibits insulin-mediated glucose utilization at the major
site of IR namely, skeletal muscle. An additional study by
Laakso et al. showed that epinephrine impairs the ability
of insulin to increase SM glucose extraction in humans
[82].
In summary, excessive catecholamines in patients with
pheochromocytoma can induce or aggravate IR in periph-
eral tissues including SM, while the surgical treatment of
pheochromocytoma can reverse the hyperinsulinemia and
cardiometabolic abnormalities observed in these patients
[79].
4.2.5. Adrenal Incidentalomas and IR. Adrenal incidentalo-
mas (AIs) are deﬁned as randomly discovered adrenal
masses, which are diagnosed by abdominal ultrasound
or computed tomography scan, performed for unrelated
causes. Recent literature suggests that 10%–20% of solid AIs
demonstrate a subclinical hormonal dysfunction, which may
place patients at a higher risk for metabolic derangements
such as IR [83]. Subclinical hypercortisolism is the most
common abnormality detected in patients with AIs, with
an average incidence of 9% [84]. Patients with AIs have a
higher prevalence of diabetes or glucose intolerance (20%–
75%), compared with the general population [85]. AIs are
considered to be both a cause and an eﬀect of hyperinsuline-
mia. The alternative hypothesis that AIs are actually caused
by hyperinsulinemia has been formulated by Reincke et al.
[86], who studied 13 patients with AIs and found that they
were all insulin resistant. He also observed a proliferative
eﬀect of insulin on adrenal cell lines in vitro, indicating
that insulin can stimulate adrenocortical tumor formation.
The proposed theory was that AIs can be perceived as the
clinical result of sustained hyperinsulinemia, just as PCOS
is regarded as the result of insulin-mediated stimulation of
ovary growth [86].
In a study from Japan, all 12 patients with AIs exhibited
IR, based on the steady state of plasma glucose [87]. After
surgicalremovalofthetumors,steadystateofplasmaglucose
was signiﬁcantly decreased, compared to pre-adrenalectomy
values. A further study by Ivovic et al. assessed insulin
sensitivityin22patientswithAIsandconcludedthatpatients
with AIs manifested lower insulin sensitivity than healthy
controls [88].
Trying to provide an explanation for the increased risk of
developing IR in patients with nonfunctioning AIs (NFAIs),
Ermetici et al. have recently formulated the hypothesis
of adipokine involvement [89]. Plasma IL-6, adiponectin,
resistin, TNF-a, and monocyte chemoattractant protein 1
(MCP-1) levels were all found to be signiﬁcantly higher in
patients with NFAIs compared to controls. The pathogenetic
roleofproinﬂammatorycytokinesinpatientswithAIsmerits
deﬁnitely further investigation.
Inarecentstudybyourresearchteam[90],in29patients
withNFAIs,wedemonstratedsigniﬁcanthepaticandperiph-
eral IR, documented by both higher fasting glucose and
insulin levels and abnormal glucose tolerance data, as well as
an increased prevalence of several components of metabolic
syndrome, such as hypertension, dyslipidemia, fatty liver
disease, and central obesity. It is, therefore, useful to evaluate
routinely IR in patients with AIs, since results can be quite
helpful in clinical decision making [87].
4.3. Thyroid Disorders and Muscle IR. Thyroid hormones
(THs) constitute important mediators of body metabolism
and aﬀect various metabolic aspects involving glucose and
insulin metabolism, through a variety of mechanisms. Data
from animal studies have shown that THs play a key role
in the regulation and activation of insulin receptor and
glucose transporter proteins, in signaling pathways and in
the expression of diﬀerent isoforms of SM myosin heavy
chains [91]. In addition, THs regulate the diﬀerentiation,8 Journal of Biomedicine and Biotechnology
growth, and metabolism of virtually every cell in the human
body. In SM, triiodothyronine (T3) regulates muscle ﬁber
type and mitochondrial content through a genomic action,
consisting in a direct modulation of gene transcription
by ligand-dependent activation of TH receptors (TRs) and
speciﬁc TH response elements (TREs). Other TH eﬀects,
such as modulation of ion channel activity, intracellular
Ca2+ mobilization, phospholipase, and kinase activation,
have been attributed to nongenomic actions of TH. This
mode of action explained the TH-induced activation of
a signaling cascade involving phospholipase C activation,
inositol triphosphate (IP3) accumulation, intracellular Ca2+
mobilization and phosphorylation of PKC and ERK 1/2,
resulting ultimately in activation of plasma membrane
Na+/H+ exchangers and increased intracellular pH in rat
SM cells [92]. Furthermore, with the same mode of action,
T3 induces a rapid phosphorylation of both p38 and
AMPK (AMP-dependent kinase) in SM ﬁbers and stimulates
mitochondrial biogenesis [93].
4.3.1. Hypothyroidism and Muscle IR. Hypothyroidism (HP)
has been associated with disorders of glucose and insulin
metabolism, involving defective insulin secretion in response
to glucose, hyperinsulinemia, altered peripheral glucose
disposal, and IR.
According to in vivo data, HP is associated with a
decreased glucose-induced insulin secretion by the β cells
due to changes in the physicochemical properties of the islet
membranes and decreased amount of islets [94].
In addition, it is suggested that HP is an insulin resistant
state. Interestingly, even subtle decreases in the levels of
TH within the normal range have been shown to correlate
inversely with markers of IR [95]. In vivo data, emerging
from studies in propylthiouracil-induced hypothyroid ani-
mals during euglycemic-hyperinsulinemic clamps, showed
an association of HP with an adipokine-mediated IR [96].
Mitrou et al. showed that euglycemic patients with clinical
and subclinical HP were insulin resistant. In a recent study,
thesameauthorssupportedtheimportantroleofadipokines
in IR, showing a meal-induced IL-6 increase, primarily
involved in the observed IR, and a concomitant increase of
TNF-α, which seems to be the result rather the cause in this
process [4].
The mechanisms linking HP with IR in general and
in SM in particular are still under investigation. IR in HP
is associated with a negative regulation of one or more
intracellular enzymes involved in glucose catabolism [97].
An impaired translocation of GLUT4 transporters on the
plasma membrane has been also observed in the monocytes
of subjects with clinical and subclinical HP, in relation
to a decreased IMGU [98]. Dimitriadis et al. documented
a decreased glycogen synthesis rate at supraphysiological
insulin concentrations in SM of hypothyroid rats, as well as
a decreased rate of glucose oxidation at all insulin concen-
trations [99, 100]. An eﬀect of TH on insulin receptors has
been suggested, but the existing data are rather conﬂicting,
supporting either no relationship between thyroid status
and the aﬃnity of insulin receptors or diminished high
aﬃnity insulin receptors (HAIRs) in HP [101]. The eﬀect
of TH on insulin action in peripheral tissues such as SM
has not been studied systematically in vivo. Dimitriadis et
al. demonstrated a meal-induced increase in plasma insulin
levels in subjects with HP and an unchanged rate of glucose
uptake in the forearm muscles and AT, indicating that IR
is possibly the result of diminished blood ﬂow in AT and
SM [96]. In support of this, Rochon et al. showed decreased
forearm and AT blood ﬂow and glucose disposal rates
in patients with HP, during euglycemic-hyperinsulinemic
clamps [102].
It is obvious that, although HP constitutes an insulin
resistant state, more studies need to be done in order to
clarify the underlying pathogenetic mechanisms. However,
it has to be mentioned that IR appears to be similar in
patients with overt clinical and subclinical HP [103, 104],
while treatment with thyroxine does not restore IMGU in
the forearm of patients with HP, suggesting that TH per se
may not be entirely responsible for this manifestation, which
seems to be a more complex interaction between tissues and
molecules.
4.3.2. Hyperthyroidism and Muscle IR. Hyperthyroidism
(HPR) is also associated with metabolic abnormalities,
including disorders of the glucose and insulin metabolism
[105].
Insulin secretory capacity seems to be disrupted in HPR,
but the existing data are rather heterogeneous, suggesting
increased, normal, or decreased insulin secretion. This
estimationhasbeenbasedonthemeasurementofcirculating
C-peptide levels. However, when individually derived C-
peptide kinetic parameters were measured, the insulin secre-
tory rate was signiﬁcantly increased, possibly reﬂecting an
increased response of β cell to glucose, under increased TH
levels. The limitation of these studies is the use of C-peptide
as a marker of insulin secretion, which is biased, given its
rapid clearance from the circulation in HPR [106]. However,
an increase in the β-cell mass in HPR has been also reported
[107]. In addition, Liggett et al. [108] showed an increased
insulin secretory response to epinephrine (increased plasma
C-peptide) after T3 administration, indicating an increased
insulin secretory rate in HPR [108].
HPR has been also associated with hyperinsulinemia,
which is considered to be compensatory for the increased
insulin clearance [103, 104]. Insulin action and IMGU in
HPR are ill deﬁned, either in general, or in SM in particular.
In vitro and in vivo studies of IMGU using euglycemic
hyperinsulinemic clamps showed either normal or increased
IMGU [109–111]. However, IR has been documented in
HPR, especially in the liver, since there is still uncertainty
concerning the involvement of other peripheral tissues,
includingSM.Dimitriadisetal.documentedIRatthefasting
state in AT in HPR, which was suppressed postprandially,
stimulating the glucose uptake in SM [112]. The same
authors documented a postmeal induced hyperinsulinemia
in subjects with HPR, as well as IR at the level of SM [113].
However, there are only few data regarding the under-
lying pathogenetic mechanisms of IR in HPR. The existing
data regarding the number of high and low aﬃnity insulin
receptors are conﬂicting, suggesting either an increased orJournal of Biomedicine and Biotechnology 9
unaltered expression in HPR [114]. A decreased insulin
stimulated glycogen synthesis has been also reported in SM
from hyperthyroid subjects, indicating IR at the level of
SM [103, 104]. Dimitriadis et al. documented a markedly
decreased rate of IMGU in SM, which was compensated
by an increase in blood ﬂow, due to changes either in
cardiac or in vascular function [113]. The same authors
have demonstrated an IGF-1-induced increase in GLUT3
and GLUT4 translocation on the monocyte surface in HPR
subjects [99].
A decreased insulin-mediated stimulation of major
intracellular pathways of glucose metabolism has been also
reported [99, 103, 109]. HPR has been associated with an
increased activity and density of β-adrenergic receptor in SM
[108, 115], as well as a decreased muscle oxidative capacity
[116].
HPR is generally thought to be an insulin-resistant
state, but further studies are deﬁnitely needed in order to
provethisassociationandrevealtheunderlyingpathogenetic
mechanisms.IthasbeengenerallysuggestedthatTHsarenot
the only factors involved in the initiation of the IR cascade,
but they most commonly interact with various tissues and
molecules, in order to regulate glucose metabolism and
insulin action.
5. Summary and Conclusions
SM constitutes an insulin-responsive peripheral tissue with a
major role in maintaining systemic glucose metabolism. In a
general overview of insulin-resistant states, including PCOS
as well as adrenal and thyroid disorders, IR in SM appears to
beaclinicallyimportantmanifestation.Speciﬁcalterationsat
the insulin receptor level or the signal transduction pathway
have been suggested as the main underlying pathogenetic
mechanisms which lead to impaired IMGU and defective
glycogen synthesis.
In PCOS, muscle IR has been associated with abnormal
phosphorylationofinsulin-signalingproteins,alteredmuscle
ﬁber composition, reduced transcapillary insulin delivery,
decreased glycogen synthesis, and impaired mitochondrial
oxidative metabolism.
The metabolic abnormalities associated with hyper-
secreting adrenal disorders constitute the end result of the
adverse eﬀects of adrenal hormones on various components
of insulin action and glucose metabolism. Aldosterone is
associated with IR in SM either directly through its eﬀects
on the insulin receptor function and metabolic signaling
cascade,orindirectlythroughoxidativestressinduction.GCs
reduce IMGU in SM, either directly by perturbing insulin-
signaling and glycogen synthesis, or indirectly through
unfavorable changes in protein and lipid metabolism. Cat-
echolamine excess can induce or aggravate IR in SM.
Furthermore, AIs—including NFAIs—are characterized by
an increased prevalence of generalized and muscle IR,
possibly due to the subclinical proinﬂammatory milieu and
the biochemically silent endocrine abnormalities.
Thyroid disorders, including both hypo- and hyper-
thyroidism, have been associated with IR in SM and
altered peripheral glucose disposal, due to impaired GLUT4
translocation, decreased glycogen synthesis, downregulated
intracellular glucose catabolism, altered blood ﬂow, and
decreased muscle oxidative capacity.
Based on the data presented herein, it is strongly empha-
sized that all patients with common endocrine disorders
such as PCOS as well as adrenal and thyroid disorders,
should undergo a thorough metabolic evaluation, since IR—
particularly at the level of SM—appears to be a prominent
feature in these states. Far more clinical and experimental
studies are required in order to fully clarify the underlying
pathophysiology of the clinically meaningful relationship
between endocrine disease and impaired SM insulin sensi-
tivity.
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